SCHEMBL12404682

SCHEMBL12404682

CCCC(NC(C)(C)C)C(=O)C(=O)NC(C)Cc1c[nH]c2ccc(C(C)=O)cc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 2/20 0.44
HTR1D P28221 2/20 0.44
HTR1B P28222 2/20 0.44
CYP1A2 P05177 2/20 0.36
CYP2D6 P10635 2/20 0.36
CYP2C9 P11712 2/20 0.36
HSD17B10 Q99714 1/20 0.36
CTSL P07711 1/20 0.36
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
MAPK1 P28482 1/20 0.36
GPR84 Q9NQS5 1/20 0.35
ACE P12821 1/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
MMP2 P08253 2/20 0.35
MMP9 P14780 2/20 0.35
MMP8 P22894 2/20 0.35
NPBWR1 P48145 1/20 0.35
MCHR1 Q99705 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14943212 0.90 HTR1A (0.47) HTR1AHTR1DHTR1BCYP1A2CYP2D6
SCHEMBL12482186 0.89 HTR1A (0.46) HTR1AHTR1DHTR1BCYP1A2CYP2D6
SCHEMBL12401679 0.84 HTR1A (0.50) HTR1AHTR1DHTR1BCYP1A2CYP2D6
SCHEMBL16328220 0.73 HTR1A (0.53) HTR1AHTR1DHTR1BCYP1A2CYP2D6
SCHEMBL12401699 0.72 MTNR1A (0.58) CYP1A2CYP2D6KDM4EALDH1A1MEN1
SCHEMBL12895297 0.71 HTR1A (0.55) HTR1AHTR1DHTR1BHSD17B10KDM4E
SCHEMBL12404686 0.70 MTNR1A (0.63) HTR1ACYP1A2CYP2D6HSD17B10KDM4E
SCHEMBL2008272 0.70 HTR1A (0.67) HTR1AHTR1DHTR1BCYP1A2CYP2D6
SCHEMBL12401696 0.70 CTSK (0.41) CYP1A2CYP2C9CTSLALDH1A1KMT2A
SCHEMBL12401728 0.68 CTSK (0.40) CTSLMMP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8575208-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-11-05 US disclosed
US-8440706-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-14 US disclosed
US-7985762-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-26 US disclosed
US-7985762-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-26 US disclosed
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-07 US disclosed
US-7964624-B1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-06-21 US disclosed
US-20100272681-A1 Inhibitors of Serine Proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-28 US disclosed
US-20070179167-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed
US-20070179167-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110165120-A1 INHIBITORS OF SERINE PROTEASES PRSS1, PRSS3, PRSS2 HTR1A 2514/4885HTR1D 2720/4885HTR1B 2916/4885
US-20070179167-A1 Inhibitors of serine proteases PRSS1, PRSS3, PRSS2 HTR1A 2514/4885HTR1D 2720/4885HTR1B 2916/4885
US-20100272681-A1 Inhibitors of Serine Proteases SERPINB1, PRSS1, SPINT2 HTR1A 3156/4885HTR1D 4008/4885HTR1B 3702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.